HEMOPHILIA A AND B
-
Update on hemophilia gene therapy in Canada
Montreal, March 26, 2024 – Developments in gene therapy for hemophilia B have come fast and furious over the last several months. In October 2023,...
-
Update on coagulation products – current and in the pipeline
To access charts informing you of products in the PIPELINE, please CLICK HERE. To access charts informing you of CURRENT coagulation products, please CLICK HERE.
-
Novel treatments in bleeding disorders: The European Haemophilia Consortium Review
CLICK HERE to access the periodic review of novel treatments in hemophilia and other bleeding disorders by the European Haemophilia Consortium.
-
Opportunity to take part in a hemophilia B gene therapy trial
Hamilton, January 22, 2024 – McMaster University, in collaboration with CSL Behring, has announced a new gene therapy trial for etranacogene dezaparvovec (Hemgenix) in hemophilia...
-
Health Canada approves Beqvez gene therapy for hemophilia B
Ottawa – January 3, 2024 – Health Canada has authorized Beqvez (fidanacogene elaparvovec), gene therapy for the treatment of hemophilia B. Beqvez is indicated for...